Pharmacodynamic evaluation of mitomycin C analog BMS-181174 for potential use in intravesical bladder cancer therapy.
Yen
W C
WC
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, Columbus 43210, USA.
Au
J L
JL
D000283:Administration, Intravesical; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D016685:Mitomycin / Q000494:pharmacology; D008937:Mitomycins; D014407:Tumor Cells, Cultured / Q000187:drug effects; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D018906:Antineoplastic Agents, Alkylating; D008937:Mitomycins; D016685:Mitomycin; C055172:N-7-(2-(nitrophenyldithio)ethyl)mitomycin C